DZ BANK AG Sticks to Its Buy Rating for Bayer (0P6S)
DZ BANK AG analyst Peter Spengler maintained a Buy rating on Bayer yesterday. The company’s shares closed yesterday at €44.40.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Spengler is a 4-star analyst with an average return of 6.0% and a 64.78% success rate. Spengler covers the Basic Materials sector, focusing on stocks such as BASF SE, Brenntag AG, and Evonik.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bayer with a €37.13 average price target, representing a -16.37% downside. In a report released today, Barclays also maintained a Buy rating on the stock with a €50.00 price target.
0P6S market cap is currently €40.79B and has a P/E ratio of -220.35.
Read More on GB:0P6S:
Disclaimer & DisclosureReport an Issue
- Bayer ‘welcomes’ Supreme Court review of Durnell litigation
- U.S. Supreme Court to hear Bayer’s appeal of Roundup lawsuits, Bloomberg says
- Bayer to acquire AT-01 and AT-05 from Attralus, terms undisclosed
- Bayer, Souffle Therapeutics report global licensing agreement for siRNA therapy
- Barclays upgrades Bayer to Overweight on possible litigation overhang resolution
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.